High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-06-0494PMID 17047042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population-based prevalence of CDKN2A mutations in Utah melanoma families.

  2006cited by this paper
• Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma

  2005cited by this paper
• Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.

  2005cited by this paper
• CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families

  2005cited by this paper
• A mutation hotspot at the p14ARF splice site

  2005cited by this paper
• Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours

  2005cited by this paper
• Prevalence of 9p21 deletions in UK melanoma families

  2005cited by this paper
• A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation

  2005cited by this paper
• 16 ink 4 a / p 14 arf ) and cdkn 2 b genes in 53 melanoma index cases considered to be at heightened risk of melanoma

  2005cited by this paper
• A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred.

  2004cited by this paper
• Detection of 53 novel DNA variations within the tyrosinase gene and accumulation of mutations in 17 patients with albinism

  2004cited by this paper
• Melanoma and nonmelanoma skin cancer in patients with multiple tumours—evidence for new syndromes in a population‐based study

  2004cited by this paper
• Genetic susceptibility in familial melanoma from northeastern Italy

  2004cited by this paper
• Familial melanoma, pancreatic cancer and germline CDKN2A mutations

  2004cited by this paper
• Prospective risk of cancer in CDKN2A germline mutation carriers

  2004cited by this paper
• Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants

  2003cited by this paper
• CDKN2A as a uveal and cutaneous melanoma susceptibility gene

  2003cited by this paper
• Pancreatic carcinoma surveillance in patients with familial melanoma.

  2003cited by this paper
• Germline mutation of ARF in a melanoma kindred.

  2002cited by this paper
• Geographical variation in the penetrance of CDKN2A mutations for melanoma.

  2002cited by this paper
• CDKN2A germline splicing mutation affecting both p16ink4 and p14arf RNA processing in a melanoma/neurofibroma kindred

  2001cited by this paper
• A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.

  2001cited by this paper
• A melanoma-associated germline mutation in exon 1β inactivates p14ARF

  2001cited by this paper
• Understanding human disease mutations through the use of interspecific genetic variation.

  2001cited by this paper
• Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families

  2001cited by this paper
• Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.

  2000cited by this paper
• A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.

  2000cited by this paper
• High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

  2000cited by this paper
• MEDICINE AND

  2000influential reference
• Mutation screening of the CDKN2A promoter in melanoma families

  2000cited by this paper
• Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden)

  2000cited by this paper
• High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families

  2000cited by this paper
• CDKN2A (P16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas

  1999cited by this paper
• Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds.

  1999cited by this paper
• Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma

  1999cited by this paper
• CDKN2A variants in a population-based sample of Queensland families with melanoma.

  1999cited by this paper
• Mutation testing in melanoma families: INK4A, CDK4 and INK4D

  1999cited by this paper
• CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia

  1999cited by this paper
• Characterization of ligurian melanoma families and risk of occurrence of other neoplasia

  1999cited by this paper
• The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

  1998influential reference
• The Ink4a Tumor Suppressor Gene Product, p19 Arf , Interacts with MDM2 and Neutralizes

  1998cited by this paper
• Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.

  1998cited by this paper
• Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.

  1998cited by this paper
• CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas.

  1998cited by this paper
• ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

  1998cited by this paper
• Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.

  1998cited by this paper
• Germline CDKN2A mutations in childhood melanoma.

  1997cited by this paper
• Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds

  1997cited by this paper
• Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.

  1997cited by this paper
• Differential expression of p16INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations

  1997cited by this paper
• Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.

  1997cited by this paper
• Novel germline p16 mutation in familial malignant melanoma in southern Sweden.

  1996cited by this paper
• Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

  1996cited by this paper
• Genes, chromosomes & cancer

  1995cited by this paper
• Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds

  1995cited by this paper
• Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.

  1995cited by this paper
• Inhibition of ras-induced proliferation and cellular transformation by p16INK4

  1995cited by this paper
• CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

  1994cited by this paper
• Germline p16 mutations in familial melanoma

  1994cited by this paper
• Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus

  1994cited by this paper
• A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4

  1993cited by this paper
• Cytogenetic and molecular studies of the Philadelphia translocation in myelodysplastic syndromes. Report of two cases and review of the literature.

  1992cited by this paper
• Amino acid substitution matrices from protein blocks.

  1992cited by this paper
• The Dutch FAMMM family material: clinical and genetic data.

  1992cited by this paper
• Systemic cancer and the FAMMM syndrome.

  1990cited by this paper
• Basic local alignment search tool.

  1990cited by this paper
• Basic local alignment search tool. Journal of Molecular Biology

  1990cited by this paper
• Amino Acid Difference Formula to Help Explain Protein Evolution

  1974cited by this paper

• Melanoma: a genetics guide for surgeons.

  2026cites this paper
• Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor

  2025cites this paper
• Targeted and immunotherapy strategies in pancreatic ductal adenocarcinoma: Recent developments and insights.

  2025cites this paper
• Cutaneous Melanoma: A Review.

  2025cites this paper
• Novel susceptibility genes for non-NF2-/LZTR1-/SMARCB1-related hereditary schwannomatosis

  2025cites this paper
• Family history in melanoma risk: Revisiting criteria for surveillance

  2025cites this paper
• Cutaneous melanoma

  2025cites this paper
• Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications

  2025cites this paper
• Genetic Landscape of Familial Melanoma

  2025cites this paper
• Identifying high‐risk melanoma patients: The importance of acquiring a detailed family history

  2025cites this paper
• PANCREATIC CANCER SCREENING: A NARRATIVE REVIEW

  2024cites this paper
• Prevalence of CDKN2A, CDK4, POT1, BAP1, MITF, ATM, and TERT Pathogenic Variants in a Single-Center Retrospective Series of Patients With Melanoma and Personal or Family History Suggestive of Genetic Predisposition

  2024cites this paper
• Common skin cancers and their association with other non-cutaneous primary malignancies: a review of the literature

  2024cites this paper
• Advancements in Early Detection and Screening Strategies for Pancreatic Cancer: From Genetic Susceptibility to Novel Biomarkers

  2024cites this paper
• The ATM Ser49Cys Variant Effects ATM Function as a Regulator of Oncogene-Induced Senescence

  2024cites this paper
• Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer

  2024cites this paper
• Risk Factors and Innovations in Risk Assessment for Melanoma, Basal Cell Carcinoma, and Squamous Cell Carcinoma

  2024cites this paper
• Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

  2024cites this paper
• The risk of skin cancer in women who carry BRCA1 or BRCA2 mutations

  2024cites this paper
• TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma

  2023cites this paper
• Phenotypic and Genetic Features that Differ Between Hereditary and Sporadic Melanoma: Results of a Preliminary Study from a Single Center from Turkey

  2023cites this paper
• Multiple Primary Melanoma: A Five-Year Prospective Single-Center Follow-Up Study of Two MC1R R/R Genotype Carriers

  2023cites this paper
• Publication Trends and Hot Topics in Dysplastic Nevus Research: A 30-Year Bibliometric Analysis

  2023cites this paper
• Active natural compounds perturb the melanoma risk-gene network

  2023cites this paper
• A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma.

  2023cites this paper
• High‐ and intermediate‐risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium

  2023influential citation
• Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome.

  2023cites this paper
• CDKN2A/CDK4 status in Brazilian patients meeting clinical criteria for hereditary melanoma: a cross‐sectional descriptive trial

  2023cites this paper
• Melanoma and Glioblastoma—Not a Serendipitous Association

  2023cites this paper
• CDKN2A exon 1B deletion predisposing to melanoma and neural system tumour syndrome

  2022cites this paper
• A Genome-First Approach to Estimate Prevalence of Germline Pathogenic Variants and Risk of Pancreatic Cancer in Select Cancer Susceptibility Genes

  2022cites this paper
• Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report

  2022cites this paper
• Screening of potential novel candidate genes in schwannomatosis patients

  2022cites this paper
• Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South Texas

  2022cites this paper
• Current status of inherited pancreatic cancer

  2022cites this paper
• Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup

  2022influential citation
• Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040.

  2022cites this paper
• Anogenital dermatology: caseload analysis of new outpatient referrals at a single dermatology centre

  2022cites this paper
• LncRNA-Associated Genetic Etiologies Are Shared between Type 2 Diabetes and Cancers in the UAE Population

  2022cites this paper
• Hereditary pancreatic cancer.

  2022cites this paper
• New Insights into Melanoma Tumor Syndromes

  2022cites this paper
• Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes

  2022cites this paper
• Impact of Transcript (p16/p14ARF) Alteration on Cancer Risk in CDKN2A Germline Pathogenic Variant Carriers.

  2022cites this paper
• Cutaneous melanoma: An update on pathogenesis, prevention, and treatment

  2022cites this paper
• Why, Who and How We Should Screen for Melanoma

  2022cites this paper
• Nervous system (NS) Tumors in Cancer Predisposition Syndromes

  2022cites this paper
• Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.

  2022cites this paper
• Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review

  2022cites this paper
• Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants

  2022cites this paper
• Pancreatic cancer pathology viewed in the light of evolution

  2021cites this paper
• A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition

  2021cites this paper
• Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers

  2021cites this paper
• CDKN2A-Mutated Pancreatic Ductal Organoids from Induced Pluripotent Stem Cells to Model a Cancer Predisposition Syndrome

  2021cites this paper
• The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer

  2021cites this paper
• Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management

  2021cites this paper
• Genetic markers for characterization and prediction of prognosis of melanoma subtypes: a 2021 update.

  2021cites this paper
• Prophylactic Surgical Procedures in Plastic Surgery

  2021cites this paper
• CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations

  2021cites this paper
• Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?

  2021cites this paper
• Recognition, Staging, and Management of Melanoma.

  2021cites this paper
• CDKN2A germline alterations and the relevance of genotype-phenotype associations in cancer predisposition

  2021cites this paper
• The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of CDKN2A and CDK4

  2021cites this paper
• Computational drug repositioning identifies statins as a modifier of prognostic genetic expression signatures and metastatic behavior in melanoma.

  2021cites this paper
• Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches

  2021cites this paper
• Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer

  2021cites this paper
• Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells

  2021cites this paper
• Dysplastic nevus syndrome and pancreatic cancer: A case report.

  2021cites this paper
• A novel CDKN2A in-frame deletion associated with pancreatic cancer-melanoma syndrome.

  2020cites this paper
• FRAMe: Familial Risk Assessment of Melanoma—a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma

  2020cites this paper
• Association between a 46-SNP Polygenic Risk Score and melanoma risk in Dutch patients with familial melanoma

  2020cites this paper
• Recurrent melanoma development in a Caucasian female with CDKN2A+ mutation and FAMMM syndrome: A case report

  2020cites this paper
• Pancreatic cancer in the Australian population: identifying opportunities for intervention

  2020influential citation
• Retinoblastoma co-repressor 1 (RB) and cyclin-dependent kinase inhibitor (CDKN) as a multi-gene panel for differentiating pulmonary from non-pulmonary origin in metastatic neuroendocrine carcinomas.

  2020cites this paper
• Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression

  2020cites this paper
• Variation in cutaneous patterns of melanomagenesis according to germline CDKN2A/CDK4 status in melanoma-prone families.

  2020cites this paper
• Getting under the skin: The role of CDK4/6 in melanomas.

  2020cites this paper
• Insights into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1

  2020cites this paper
• Germline mutations predisposing to melanoma

  2020cites this paper
• Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies

  2020cites this paper
• Melanoma

  2020cites this paper
• Evolution of approaches to identify melanoma missing heritability

  2020cites this paper
• CDKN2A Gene

  2020cites this paper
• Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon.

  2020cites this paper
• The Melanoma and Breast Cancer Association: An Overview of their 'Second Primary Cancers' and the Epidemiological, Genetic and Biological correlations.

  2020cites this paper
• Characterizations of Gene Alterations in Melanoma Patients from Chinese Population

  2020cites this paper
• Cancer immunology of cutaneous melanoma: a systems biology approach

  2020cites this paper
• Overcoming Immune Evasion in Melanoma

  2020cites this paper
• Clinical Genetics and Risk Assessment of Melanoma

  2020cites this paper
• A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes

  2020cites this paper
• Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants

  2020cites this paper
• Multiple primary tumors: a case report and review of the literature

  2020cites this paper
• CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study

  2020cites this paper
• Regulatory T Cells Play an Important Role in the Prevention of Murine Melanocytic Nevi and Melanomas

  2020cites this paper
• FRAMe: Familial Risk Assessment of Melanoma—a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma

  2020cites this paper
• Inherited Contributions to Melanoma Risk

  2019cites this paper
• Familial Melanoma: Diagnostic and Management Implications

  2019cites this paper
• Progress report on the major clinical advances in patient-oriented research into familial melanoma (2013–2018)

  2019cites this paper
• The Association of Single Nucleotide Polymorphisms with Cancer Risk

  2019cites this paper
• CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients

  2019cites this paper
• GENOTYPE – PHENOTYPE CORRELATIONS IN CUTANEOUS MELANOMA PATIENTS CARRIER OF THE MITF p . E 318 K PATHOGENIC VARIANT

  2019cites this paper